Chance Cole promoted to VP at The Little Clinic
BRENTWOOD, Tenn. — The Little Clinic has promoted Chance Cole to VP business development and processes, handling business-to-business and overall business development, process improvement and nonclinical training activities.
Cole joined the company in July 2010 as The Little Clinic manager of integration. Prior to accepting a position with The Little Clinic, he spent 20 years with Kroger as a store manager, Kroger coordinator, Kroger merchandising, retail operations manager and marketplace merchandising manager.
"Chance has been an integral part of our success since he arrived, and I’m looking forward to the leadership he will provide in his new role," stated Mike Stoll, CEO for The Little Clinic. "His understanding of the inner workings of retail grocery stores makes him a perfect fit for this position."
The Little Clinic healthcare centers currently are located inside select Kroger stores in Kentucky, Tennessee and Ohio; King Soopers stores in Colorado; and Fry’s Food Stores. The Little Clinic also provides management to branded clinics in Florida and Georgia.
Forest Labs announces phase-3 trial results for depression drug
NEW YORK — A drug for major depressive disorder worked better than placebo, according to results of a late-stage clinical trial announced Thursday.
U.S. drug maker Forest Labs and French drug maker Pierre Fabre Medicament said that while the overall difference between patients treated with levomilnacipran and those treated with the placebo was not statistically significant, the drug consistently demonstrated improvement relative to the placebo over the course of the phase-3 trial.
The companies said the results differed from the findings of a previous 563-patient phase-2 study of the drug, which showed statistically significant improvement over placebo.
Dr. Reddy’s receives FDA approval for generic GERD treatment
HYDERABAD, India — Indian drug maker Dr. Reddy’s Labs has launched a generic treatment for gastroesophageal reflux disease.
The company announced Thursday the launch of pantoprazole sodium delayed-release tablets in the 20-mg and 40-mg strengths. The drug is a version of Protonix, made by Wyeth, now part of Pfizer.
Pantoprazole sodium delayed-release tablets had sales of around $1.8 billion during the 12-month period ended in September 2010, according to IMS Health.